About

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tR...

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

Follow Us

Events

Bios

Leslie J Williams, a 25-year biopharmaceutical industry veteran, is an experienced biotech CEO and board of directors’ member with demonstrated expertise in building companies, raising funds, and negotiating strategic collaborations. Leslie is founding CEO, President & Director of hC Bioscience, Inc. an innovator and leader in protein editing with tRNA based therapeutics. She also serves on the Board of Directors for Ocular Therapeutix (OCUL), Windtree Therapeutics (WINT), and CSCRI (Coral Sea Clinical Research Institute). In addition, she serves on the Editorial Advisory Board of Life Science Leader, the Advisory Board of Life Science Cares and serves as an EIR at UVA and University of Iowa. Ms. Williams was formerly the founder and CEO of ImmusanT, developing immunotherapies for autoimmune diseases and was CEO at Ventaira Pharmaceuticals developing therapies using the lung as a portal for delivery. Williams prior pharmaceutical experience includes INO Therapeutics, Merck and GSK. She was also a venture partner at Battelle Ventures where she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Before entering the industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.
Leslie Williams
Co-Founder, President & CEO
View more >>
Dave Altreuter, PhD is CTO at hC Bioscience. Since 2001 Dave has specialized in the design, translation, and development of novel drug products wherein innovative delivery has a central or critically-enabling role.
David H. Altreuter​
CTO
View more >>
Christine Foster, D. Phil., is the Chief Business Officer of hC Bioscience. Prior to joining hc Bioscience, Dr. Foster served as Chief Business Officer at Mnemo Therapeutics. She has more than 30 years of industry experience in the biopharmaceutical industry. Throughout her career, she has developed and executed strategic partnerships, including transactions in the field of genome editing with Intellia Therapeutics and Metagenomi Therapeutics; played a critical role in the execution of deals with Affini-T Therapeutics, Ionis Pharmaceuticals, Regeneron Pharmaceuticals and Novartis; and established novel co-development and co-commercialization relationships with Onk Therapeutics, SparingVision, Kyverna Therapeutics and Avencell View full bio to the right [for the side bar – Dr. Foster has led business development, alliance management and corporate development activities through key phases of growth at Acceleron Pharma, Sunovion Pharmaceuticals, Inc., Teva Pharmaceuticals, Wyeth (now Pfizer) and GlaxoSmithKline, among others. Trained as a scientist, Christine earned a D.Phil. in pharmacology from the University of Oxford and completed post-doctoral fellowships at Brandeis University in neuroscience and the University of Massachusetts Medical School in cardiovascular diseases.
Christine Foster, D. Phil.
Chief Business Officer
View more >>
Gautam is a leader in translational computational biology and a seasoned professional with an impactful 20-year track record in biotech, academia and tech industry.
Gautam Goel
Chief Data Science Officer
View more >>

Media Gallery

Press Contacts

Savannah Beaver
Media
(617) 804-0366

News & Publications